Alexion Pharmaceuticals

What Alexion Pharmaceuticals does

Alexion Pharmaceuticals is a biopharmaceutical company founded in 1992 and now operating as the wholly-owned rare disease division of AstraZeneca following a $39 billion acquisition completed in July 2021. The company develops and commercializes therapeutics for ultra-rare diseases, anchored by its proprietary expertise in complement biology and C5 complement inhibition. Its commercial portfolio includes Ultomiris (ravulizumab, a long-acting C5 inhibitor generating $4.7 billion in 2025 worldwide sales, up 19% YoY), Soliris (eculizumab, the pioneering C5 inhibitor), Strensiq and Kanuma (enzyme replacement therapies for hypophosphatasia and LAL deficiency respectively), Koselugo (a MEK inhibitor for NF1 plexiform neurofibromas), and Voydeya (a complement factor D inhibitor for PNH). The pipeline extends into next-generation C5 inhibitors (gefurulimab), PTH receptor agonists (eneboparatide), anti-fibril amyloidosis therapies (anselamimab), and genomic medicines built through the LogicBio acquisition and JCR Pharmaceuticals AAV capsid partnership. Alexion serves patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, NMOSD, generalized myasthenia gravis, hypophosphatasia, NF1, amyloidosis, and hypoparathyroidism, among others.

Alexion operates a specialty pharmaceutical revenue model with premium pricing (historically $400,000-$500,000 per patient annually for Soliris), distributing through specialty pharmacy channels reimbursed by government and commercial payers across 20+ countries in North America, Europe, and Asia Pacific. The go-to-market motion is enterprise field sales targeting rare disease specialists, supported by medical science liaisons and patient services. The company is expanding into genomic medicine and AI-powered diagnostics through the BeginNGS newborn screening partnership, LogicBio gene therapy platform integration, and an internal AI Diagnostics team applying computer vision and machine learning to shorten the multi-year rare disease diagnostic odyssey. Regulatory moats include orphan drug designations and layered exclusivity protections across multiple indications.

Name

Alexion Pharmaceuticals

Legal name

Alexion Pharmaceuticals, Inc.

Website

https://alexion.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Alexion Pharmaceuticals is a biopharmaceutical company, operating as AstraZeneca's rare disease division, that develops and commercializes specialty therapeutics — anchored by C5 complement inhibitors Ultomiris and Soliris — for patients with ultra-rare diseases including PNH, aHUS, NMOSD, gMG, and hypophosphatasia across 20+ countries.

Ownership category

akta.pro rank

Product category

Rare Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

akta.pro secondary industries

Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN), Rare Renal & Nephrology Disorder Therapies (HLAIAIAI), Neurology/CNS Gene Therapies (HLAAACAH), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG), Genetic & Genomic Rare Disease Therapeutics (HLAIAIAA)

Keywords

• Rare disease therapeutics
• Complement inhibition therapy
• Enzyme replacement therapy
• Specialty biologics
• Genomic medicine platforms

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Specialty Pharmaceutical Sales: Alexion generates revenue through the sale of rare disease therapeutics including Soliris, Ultomiris, Koselugo, Strensiq, and Kanuma. Revenue flows through specialty pharmacy distribution channels with reimbursement from government and commercial payers.
2. Royalty and Licensing Revenue: Xencor licenses its XmAb Fc domains and technologies to Alexion, generating royalty payments on Ultomiris (ravulizumab-cwvz) sales. Currently involved in a royalty dispute regarding U.S. sales.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Alexion Pharmaceuticals develops and commercializes specialty biologics for rare diseases, with a core focus on C5 complement inhibitors (Ultomiris/ravulizumab and Soliris/eculizumab), enzyme replacement therapies (Strensiq, Kanuma, and investigational efzimfotase alfa), the MEK inhibitor Koselugo, and complement factor D inhibitor Voydeya. The company also invests in genomic medicine capabilities including AAV-based gene therapy delivery and AI-powered diagnostic programs such as BeginNGS for newborn genomic screening, addressing PNH, aHUS, NMOSD, gMG, HPP, NF1, and amyloidosis.

Product overview

Alexion Pharmaceuticals, operating as AstraZeneca Rare Disease, is a biopharmaceutical company focused on rare disease therapeutics. The company offers a portfolio of complement inhibitors including Ultomiris (C5 inhibitor with $4.7B sales) and Soliris, along with enzyme replacement therapies Strensiq and Kanuma, and the MEK inhibitor Koselugo. The pipeline includes next-generation C5 inhibitors (gefurulimab), enzyme replacement therapies (efzimfotase alfa), PTH receptor agonists (eneboparatide), and amyloidosis treatments (anselamimab). Alexion also invests in AI-powered diagnostic programs like BeginNGS for genomic newborn screening. The company operates across disease areas including PNH, aHUS, NMOSD, gMG, HPP, amyloidosis, hypoparathyroidism, and NF1.

Differentiator

Problem solved

Functional benefit

Brands

• Ultomiris: Complement C5 inhibitor for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD), and immunoglobulin A nephropathy
• Soliris
• Koselugo
• Strensiq
• Kanuma
• Voydeya
• Ulinnestin (investigational)

Products and services

• Ultomiris (ravulizumab)
• Soliris (eculizumab)
• Koselugo (selumetinib)
• Voydeya (danicopan)
• Strensiq (asfotase alfa)
• Kanuma (sebelipase alfa)
• Efzimfotase alfa (ALXN1850)
• Eneboparatide (AZP-3601)
• Gefurulimab
• Anselamimab
• BeginNGS (Begin Newborn Genome Sequencing)

Quantifiable outcome

• 98.9% relapse risk reduction in AQP4-Ab+ NMOSD patients treated with Ultomiris through median follow-up of 170.3 weeks
• +4 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• MSD (Merck & Co.)coreStrategic or Co-development Partner · 28 October 2025Koselugo (selumetinib) was developed through a global strategic collaboration between AstraZeneca and MSD. Alexion commercializes Koselugo through AstraZeneca's rare disease division. The drug has received approvals in the US, EU, Japan, and other countries for neurofibromatosis type 1 with plexiform neurofibromas.
• Rady Children's Institute for Genomic MedicinecoreStrategic or Co-development Partner · 10 October 2025Alexion serves as a founding partner in the BeginNGS (Begin Newborn Genome Sequencing) program led by Rady Children's Institute for Genomic Medicine. The consortium aims to use whole genome sequencing for newborn screening to identify infants at risk for thousands of genetic diseases before symptoms appear. Alexion and hospital partners are researching AI-powered approaches to improve accuracy of genomic newborn screening.
• JCR PharmaceuticalscoreStrategic or Co-development Partner · 9 July 2025Alexion signed an $825 million deal with JCR Pharmaceuticals for adeno-associated virus (AAV) capsids to develop up to five genomic medicine programs. JCR will receive undisclosed upfront payment, up to $225 million in potential milestone payments, and up to $600 million in sales-based milestones plus tiered royalties. The capsids are designed to enhance targeted delivery of gene therapies with properties including liver avoidance or muscle/brain tissue targeting.
• LogicBio TherapeuticscoreStrategic or Co-development Partner · 3 October 2022Alexion acquired LogicBio Therapeutics in October 2022 through its AstraZeneca Rare Disease division. The acquisition aimed to enhance genomic medicine capabilities with LogicBio's technology, expertise, and platforms for gene delivery and editing. LogicBio specialized in developing gene replacement therapies for rare diseases using viral vectors.
• Amyndas PharmaceuticalsminorOthersAmyndas Pharmaceuticals brought trade secret claims against Alexion alleging improper use of confidential information during early partnership talks to launch a collaboration with a competitor. Alexion successfully defended against these claims with a court ruling in Alexion's favor in April 2026.
• Ultragenyx PharmaceuticalminorGTM or Marketing PartnerAlexion served as a sponsor for Ultragenyx's Rare Bootcamp event in Boston in April 2026, a free multi-day forum helping families of children with rare diseases learn about drug development research and connect with experts. The event featured over 20 sessions covering the full spectrum from early science to regulatory approval.
• Biogen, EMD Serono, Novartis, Sanofi, Genentech, AbbVieminorGTM or Marketing PartnerAlexion joined multiple pharmaceutical companies as a sponsor of the We Are ILL sixth annual Wellness Week(end) in Atlanta, a transformative gathering for Black women living with autoimmune diseases. This reflects Alexion's commitment to health equity in rare disease communities.
• Sanofi Genzyme, Takeda Pharmaceuticals, BioMarin, Amicus TherapeuticsminorOthersAlexion is identified as one of the key leading companies in the enzyme replacement therapy market alongside Sanofi Genzyme, Takeda Pharmaceuticals, BioMarin, and Amicus Therapeutics, reflecting its competitive positioning in rare disease therapeutics.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Vertex Pharmaceuticals: Vertex develops specialty pharmaceuticals for serious diseases including rare disorders (cystic fibrosis, sickle cell), with similar focus on high-price, small-population therapeutics and a comparable business model of franchise dominance in niche indications.
• BioMarin Pharmaceutical: BioMarin is a rare disease-focused biopharma with enzyme replacement therapies and gene therapies for conditions like HPP, LAL deficiency, and hemophilia A — directly overlapping with Alexion's Strensiq and Kanuma franchises and pipeline priorities.
• Alnylam Pharmaceuticals: Alnylam develops RNA interference therapeutics for rare diseases including hATTR amyloidosis, overlapping with Alexion's amyloidosis franchise and rare disease commercial model targeting specialty physicians and patients.
• Ionis Pharmaceuticals: Ionis is an antisense oligonucleotide pioneer developing therapies for rare neurological, cardiovascular, and metabolic diseases with a similar R&D model targeting underserved rare disease populations and recently appointed former Alexion CEO Ludwig Hantson to its board.
• Ultragenyx Pharmaceutical: Ultragenyx is a pure-play rare disease biotech developing therapeutics for metabolic, neuromuscular, and skeletal disorders with comparable business model targeting high unmet need rare populations with premium-priced biologics.
• Amicus Therapeutics: Amicus Therapeutics develops therapies for rare metabolic diseases including Fabry disease and Pompe disease, competing in the enzyme replacement space alongside Alexion's Strensiq and Kanuma.

Broad incumbents

• Regeneron Pharmaceuticals: Regeneron operates a broader biopharma portfolio but includes rare disease therapeutics (e.g., evinacumab for HoFH) with overlapping specialty distribution models and high-price biologics targeting small patient populations.
• Sanofi (Genzyme): Sanofi's Genzyme division is a foundational rare disease franchise with enzyme replacement therapies (Fabrazyme, Cerezyme, Myozyme) directly competing with Alexion's Strensiq and Kanuma in the enzyme replacement market.
• Takeda Pharmaceutical: Takeda's rare disease franchise (built on the Shire acquisition) competes across hematology, neurology, and metabolic rare diseases with comparable specialty pharmaceutical distribution and pricing models.
• Novartis (Gene Therapy): Novartis has built a rare disease and gene therapy capability (Zolgensma for SMA) directly relevant to Alexion's genomic medicine expansion via LogicBio and JCR AAV capsid partnership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alexion-pharmaceuticals
• Xx.com/AlexionPharma
• Facebookfacebook.com/AlexionPharmaceuticalsInc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A9 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alexion Pharmaceuticals